COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics to Resume Accrual in Phase 3 Clinical Trial of Tedopi® in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
07/12/2017
Independent Data Monitoring Committee recommends future recruitment focused on patients who have previously failed immune checkpoint inhibitor treatment New strategy adjusts for rapidly-evolving clinical practice with [...]
ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION
07/12/2017
GHENT, Belgium, 7 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from the Phase III [...]
Novartis tender offer for Advanced Accelerator Applications commences
07/12/2017
Basel, December 7, 2017 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), [...]
INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2018
07/12/2017
Innate Pharma announceS ITS FINANCIAL CALENDAR FOR 2018 Marseille, France, December 7, 2017, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces its financial calendar for [...]
INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018
07/12/2017
INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2018 Marseille, le 7 décembre 2017, 7h00 CET Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui son calendrier financier pour l'année 2018 : 8 [...]
INNATE PHARMA : NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT DECEMBER 4, 2017
07/12/2017
NUMBER OF SHARES AND VOTING RIGHTS OF Innate Pharma AS AT December 4, 2017 Marseille, France, December 7, 2017, 7:00 AM CET Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 [...]
INNATE PHARMA : NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 4 DECEMBRE 2017
07/12/2017
nouveau NOMBRE D'ACTIONS ET DE DROITS DE VOTE d'InnatE Pharma AU 4 décembre 2017 Marseille, le 7 décembre 2017, 7h00 CET Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l' [...]
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $276 Million
07/12/2017
LONDON, Dec. 06, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) ("GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its [...]
Resverlogix Repays $68.8 Million Loan
07/12/2017
CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX ) announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of [...]
Myriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
07/12/2017
SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to [...]
Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B
06/12/2017
PHILADELPHIA and NEW YORK, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE ), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. ( [...]
G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/12/2017
RESEARCH TRIANGLE PARK, N.C., Dec. 06, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced the grant of an equity inducement award to Barclay (Buck) [...]
Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
06/12/2017
BURLINGTON, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President [...]
US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
06/12/2017
SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP ) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses [...]
Purepoint Uranium Closes Final Tranche of $1,200,000 Private Placement
06/12/2017
Not for Dissemination in the United States or through U.S. Newswire Services TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (TSXV:PTU) (the “ Company ”) is pleased to announce the closing of the [...]
Analogic Announces Results for the First Quarter Ended October 31, 2017 and Declares Quarterly Cash Dividend
06/12/2017
PEABODY, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq: ALOG ), enabling the world's medical imaging and aviation security technology, today announced results for its first quarter ended October [...]
WishBone Medical Inc. Names Jean-Pierre Capdevielle as Chief Strategy Officer and Board Member
06/12/2017
WARSAW, Ind., Dec. 06, 2017 (GLOBE NEWSWIRE) -- WishBone Medical, Inc., a new pediatric orthopedic company in Warsaw, Indiana, announced that Jean-Pierre “JP” Capdevielle has taken on the role of Chief Strategy Officer [...]
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
06/12/2017
Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and an early response with separation of [...]
Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)
06/12/2017
Objective Response Rate (ORR) = 31% (Centrally Reviewed); 34% (Locally Assessed) Median Duration of Response (DOR) = 9.1 Months (Centrally Reviewed); 7.6 Months (Locally Assessed) Clinical Benefit Rate at 6 Months = 45 [...]

Pages